Amendment No. 3, dated October 8, 2010, to the Collaboration Agreement



 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Exhibit 10.68 
 AMENDMENT NO. 3
TO THE COLLABORATION AGREEMENT 
 BETWEEN 

EXELIXIS, INC., AND BRISTOL-MYERS SQUIBB
COMPANY 
  
  

THIS AMENDMENT NO. 3 (“Amendment No. 3”) to the Agreement
(defined below) is effective as of October 8, 2010 (the “Amendment No. 3 Effective Date”) by and between Exelixis, Inc., a Delaware corporation located at 170 Harbor Way, P.O. Box 511, South San Francisco,
California 94083-0511 (“Exelixis”) and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to individually
as a “Party” and collectively as the “Parties”. 

WHEREAS, Exelixis and BMS entered into that certain Collaboration Agreement effective as of
December 11, 2008, amended to be effective as of December 18, 2008, and further amended as of September 1, 2009 (the agreement and amendments, collectively, the “Agreement”) for the purposes of applying Exelixis
technology and expertise to the discovery, lead optimization and characterization of small molecule compounds, including XL184 and XL281, and providing for the development and commercialization of novel therapeutic and prophylactic products based on
such compounds; and 
 WHEREAS, the Parties desire to amend various sections of the Agreement, as set
forth below. 
 NOW, THEREFORE, in consideration of the premises and mutual
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
 AGREEMENT 
  

	1.	AMENDMENT OF THE AGREEMENT 


The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment No. 3 Effective Date.
To the extent that the Agreement is explicitly amended by this Amendment No. 3, the terms of this Amendment No. 3 will control where the terms of the Agreement are contrary to or conflict with the following provision. Where the Agreement
is not explicitly amended, the terms of the Agreement will remain in full force and effect. Capitalized terms used in this Amendment No. 3 that are not otherwise defined herein shall have the same meanings as such terms have in the Agreement.

 1.1 Amendment of Section 7.6(a) of the Agreement. The Parties agree to delete Section 7.6(a) of the Agreement
in its entirety and replace it with the following: 







 “7.6(a) [Intentionally left blank.]” 

1.2 Amendment of Section 7.8(a) of the Agreement. The Parties agree to delete Section 7.8(a) of the Agreement in its
entirety and replace it with the following: 
 “7.8(a) Joint Patent Committee. 

(i) Establishment & Meetings. Promptly after the Effective Date (as defined in the TGR5 License Agreement), the Parties
shall establish a committee (the “Joint Patent Committee” or “JPC”). The JPC shall be composed of at least (1) representative from each Party, at least one of which shall be a patent counsel for
such Party. Each Party may change its representative(s) by giving the other Party at least [ * ] prior written notice. The JPC shall meet within [ * ] after the Effective Date (as defined in the TGR5 License Agreement), and once per [ * ]
thereafter, or as may be requested by either Party as necessary, by teleconference, videoconference or in person (as determined by the JPC). 
 (1) Duties. Promptly after the Effective Date (as defined in the TGR5 License Agreement), [ * ] shall oversee (subject to Sections 7.8(b)(ii), (iv) and (v) below) the
preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all [ * ] Patents, [ * ] Patents Controlled by [ * ], and [ * ] Patents that in each case are [ * ] (the “[ * ]
Patents”), provided that, unless otherwise agreed by the Parties, such responsibilities shall be carried out by: (A) [ * ] by [ * ] the [ * ], unless there exists [ * ] of [ * ] and [ * ]; (B) [ * ] by [ * ], but only in the case
where [ * ] described in subsection (A) had [ * ] of [ * ]; or (C) [ * ] in conjunction with [ * ] described in the preceding subsection (A) or (B), as applicable. [ * ], or [ * ], shall provide [ * ] with an update of the filing,
prosecution and maintenance status for each of the [ * ] Patents on a periodic basis, and shall use commercially reasonable efforts to consult with and cooperate with [ * ] with respect to the filing, prosecution and maintenance of the [ * ]
Patents, including providing [ * ] with drafts of proposed filings to allow [ * ] a reasonable opportunity for review and comment before such filings are due. [ * ], or the external counsel, shall provide to [ * ] copies of any papers relating to
the filing, prosecution and maintenance of the [ * ] Patents promptly upon their being filed and received. 
 (2)
Decisions. Subsequent to the Effective Date (as defined in the TGR5 License Agreement), in the event of a dispute between the Parties with regard to the preparation, filing, prosecution (including any interferences, reissue proceedings and
reexaminations) and maintenance of any [ * ] Patent, the matter shall be promptly referred to the [ * ] of Exelixis and [ * ] for BMS. If these two (2) individuals are unable to resolve the dispute promptly, then the matter shall be promptly
elevated to the [ * ] of Exelixis and the [ * ] of BMS. If these two (2) individuals are unable to resolve the dispute promptly, then, subject to Sections 7.8(a)(i)(3), 7.8(a)(i)(4), 7.8(a)(ii), [ * ] of the ROR Collaboration Agreement,
and [ * ] of the ROR Collaboration Agreement, BMS shall have the final decision, except if such decision: (A) conflicts with the terms of the Agreement; (B) would result in [ * ] described in [ * ] or a [ * ] of the [ * ]; or
(C) materially impacts [ * ] prosecution of Patents that [ * ] a [ * ], in which case of subsection 7.8(a)(i)(2)(A) - (C), [ * ] shall have the final decision 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  
 2 








 (3) Limitation on Subsection 7.8(a)(i)(2)(B). If [ * ] reasonably believes that
filing a new patent application covering a [ * ] (other than the [ * ] of a [ * ]) would result in potential claims [ * ] for [ * ], and if [ * ] disputes with [ * ] that such patent application should be filed, then such dispute shall be discussed
as described in the first two (2) sentences of Section 7.8(a)(i)(2), and, if still unresolved, shall be arbitrated pursuant to Section [ * ] of the ROR Collaboration Agreement, and [ * ] shall not have the right to exercise
its final-decision making authority pursuant to Subsection 7.8(a)(i)(2)(B) unless the dispute is resolved in [ * ] favor. 
 (4) Limitation on Subsection 7.8(a)(i)(2)(C). [ * ] hereby covenants that it shall not, without the prior written consent of [ * ] (which shall not be unreasonably delayed or conditioned), during
the term of this Agreement, [ * ] the decision-making authority granted to [ * ] pursuant to Subsection 7.8 (a)(i)(2)(C) [ * ] that is [ * ] existing as of the Effective Date or [ * ]. Furthermore, if [ * ] the decision-making authority
granted to [ * ] pursuant to Subsection 7.8 (a)(i)(2)(C) [ * ] by [ * ], [ * ] or [ * ], and such [ * ] is [ * ] or [ * ] a [ * ] that is [ * ], then [ * ] and [ * ] shall agree, pursuant to Section [ * ] of the ROR Collaboration
Agreement, on [ * ] the decision-making authority granted to [ * ] pursuant to Subsection 7.8 (a)(i)(2)(C). 

(ii) Abandonment. In no event shall [ * ] knowingly permit any of the [ * ] Patents to be abandoned in any country, or elect not
to file a new patent application claiming priority to a patent application within the [ * ] Patents either before such patent application’s issuance or within the time period required for the filing of an international (i.e., Patent Cooperation
Treaty), regional (including European Patent Office) or national application, without [ * ] written consent (such consent not to be unreasonably withheld, delayed or conditioned) or [ * ] otherwise first being given an opportunity to assume full
responsibility (at [ * ] expense) for the continued prosecution and maintenance of such [ * ] Patents or the filing of such new patent application. Accordingly, [ * ], or [ * ], shall provide [ * ] with notice of the allowance and expected issuance
date of any patent within the [ * ] Patents, or any of the aforementioned filing deadlines, and [ * ] shall provide [ * ] with prompt notice as to whether [ * ] desires [ * ] to file such new patent application. In the event that [ * ] decides
either: (A) not to continue the prosecution or maintenance of a patent application or patent within the [ * ] Patents in any country; or (B) not to file such new patent application requested to be filed by [ * ], [ * ] shall provide [ * ]
with notice of this decision at least [ * ] prior to any pending lapse or abandonment thereof, and [ * ] shall thereafter have the right to assume responsibility for the filing, prosecution and maintenance of such patent or patent application. In
the event that [ * ] assumes such responsibility for such filing, prosecution and maintenance, [ * ] shall no longer have the responsibility for such filing, prosecution and maintenance of such patent applications and patents, and [ * ] shall
cooperate as reasonably requested by [ * ] to facilitate control of such filing, prosecution and maintenance by [ * ]. In the case where [ * ] takes over the filing, prosecution or maintenance of any patent or patent application as set forth above,
such patent or patent application shall [ * ] be [ * ] the [ * ], and [ * ] shall [ * ] such patent or patent application. 

(iii) Filing, Prosecution and Maintenance of Sole Invention Patents Controlled by BMS. In accordance with this
Section 7.8 (a)(iii), BMS shall be responsible for the filing, prosecution (including any interferences, reissues and reexaminations) and 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  
 3 








 
maintenance of all Sole Invention Patents Controlled by BMS. [ * ] shall provide to Exelixis copies of any papers relating to the filing, prosecution and maintenance of the Sole Invention Patents
Controlled by BMS promptly upon their being filed and received. 
 (iv) Patent Term Extension. Exelixis and BMS shall
each cooperate with each another and shall use commercially reasonable efforts in obtaining patent term extension (including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in
any country with respect to patent rights covering the Products. If elections with respect to obtaining such patent term extensions are to be made, [ * ] shall have the right to make the election to seek patent term extension or supplemental
protection. 
 (v) Exelixis Right to Separate Claims. To the extent that any Sole Invention Patent of Exelixis contains
claims that cover compounds that are not Collaboration Compounds (such compounds, “Separable Compounds”), Exelixis shall have the right to separate any claims that cover such Separable Compounds (and not Collaboration Compounds) and
to file such claims in a separate application (e.g., a continuation, continuation-in-part, or divisional application). Exelixis shall notify BMS in writing prior to separating such claims, and such separation shall be at Exelixis’ sole
expense.” 
 1.3 Amendment of Section 7.10 of the Agreement. The Parties agree to delete Section 7.10 of
the Agreement in its entirety and replace it with the following: 
 “7.10 [Intentionally left blank.]”

 1.4 Amendment of Section 9.1(a) of the Agreement. The Parties agree to delete Section 9.1(a) of the Agreement
in its entirety and replace it with the following: 
 “9.1(a) Prior to Commercialization. Subject to Sections
9.1(a)(i), 9.2 and 9.3, [ * ], [ * ] (directly or indirectly, and either with or without a bona fide collaborator) outside the scope of this Collaboration any programs: (I) that [ * ] that [ * ] of [ * ]; or (II) where [ * ] that [ * ];
provided, however, that, [ * ], the foregoing shall [ * ] (either alone or with a Third Party) [ * ] of a [ * ] that [ * ]: (A) [ * ] that [ * ] and/or [ * ] a [ * ] that [ * ] of such [ * ], [ * ] (B) [ * ] that is [ * ] or [ * ].

 (i) [ * ] of a Product. Upon either (A) the [ * ] of the [ * ] Products [ * ] with respect to [ * ] or [ * ];
(B) the [ * ] of [ * ] Products with respect to [ * ] or [ * ] pursuant to Section [ * ]; or (C) the [ * ] of [ * ] or [ * ] pursuant to Section [ * ], [ * ] (directly or indirectly, and either with or without a bona
fide collaborator) outside the scope of this Collaboration programs to [ * ] that [ * ].” 
 1.5 Amendment of
Section 14.4 of the Agreement. The Parties agree to delete Section 14.4 of the Agreement in its entirety and replace it with the following: 
 “14.4 Entire Agreement; Amendments. This Agreement, the license 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  
 4 








 
agreement (for the discovery, development and commercialization of compounds that agonize the target known as TGR5) and that is dated as of the Amendment No. 3 Effective Date (the
“TGR5 License Agreement”), the collaboration agreement (for the discovery, development and commercialization of compounds that antagonize the target known as ROR) and that is dated as of the Amendment No. 3 Effective Date (the
“ROR Collaboration Agreement”), and the letter agreement that is dated as of the Amendment No. 3 Effective Date and that describes Exelixis’ creation of a licensing Affiliate (the “Letter Agreement”), set
forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and
understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement, the TGR5 License
Agreement, the ROR Collaboration Agreement, and the Letter Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each
Party.” 
  

	2.	MISCELLANEOUS 

 2.1 Full Force and Effect. This Amendment No. 3 amends the terms of the Agreement and is deemed incorporated into, and governed by all other terms of, the Agreement. The provisions of the
Agreement, as amended by this Amendment No. 3, remain in full force and effect. 
 2.2 Further Actions. Each Party
shall execute, acknowledge and deliver such further instruments, and do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Amendment No. 3. 

2.3 Counterparts. This Amendment No. 3 may be executed in two (2) or more counterparts, each of which shall be an
original and all of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile, or electronically in PDF format, each of which shall be binding when sent. 

Signature page follows 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  
 5 








 IN WITNESS WHEREOF, the
Parties have caused this Amendment No. 3 to be executed by their duly authorized representatives. The date that this Amendment No. 3 is signed shall not be construed to imply that the document was made effective on that date. 

 

									
	Bristol-Myers Squibb Company	 		 	Exelixis, Inc.
					
	Signature:	 	         /s/ Jeremy Levin
	 		 	Signature:	 	         /s/ Michael Morrissey

					
	Name:	 	             Jeremy Levin
	 		 	Name:  	 	           Michael Morrissey

					
	Title:	 	         Senior Vice President
	 		 	Title:   	 	            CEO

					
	Date:	 	
             10/08/2010
	 		 	Date:   	 	
           10/08/2010



  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  
 6